Agilent Technologies (NYSE:A) Given New $180.00 Price Target at Stifel Nicolaus

Agilent Technologies (NYSE:A) had its target price boosted by analysts at Stifel Nicolaus from $170.00 to $180.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. Stifel Nicolaus’ price target points to a potential upside of 14.49% from the company’s current price.

Several other research analysts also recently issued reports on A. Barclays lifted their price target on Agilent Technologies from $150.00 to $175.00 and gave the stock an “overweight” rating in a research note on Thursday. Wells Fargo & Company dropped their target price on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Wolfe Research restated a “hold” rating on shares of Agilent Technologies in a research report on Tuesday, June 2nd. Royal Bank Of Canada increased their price target on shares of Agilent Technologies from $155.00 to $185.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, Robert W. Baird lifted their price objective on Agilent Technologies from $155.00 to $156.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Agilent Technologies currently has a consensus rating of “Moderate Buy” and an average price target of $170.33.

Agilent Technologies Price Performance

Shares of A stock traded up $2.13 during midday trading on Thursday, reaching $157.22. 1,992,931 shares of the company traded hands, compared to its average volume of 2,232,849. The firm’s 50 day simple moving average is $139.16 and its two-hundred day simple moving average is $126.65. The firm has a market cap of $44.40 billion, a PE ratio of 31.56, a price-to-earnings-growth ratio of 2.73 and a beta of 1.25. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.10 and a quick ratio of 1.62. Agilent Technologies has a 1-year low of $108.35 and a 1-year high of $163.75.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.13. The firm had revenue of $1.88 billion during the quarter, compared to the consensus estimate of $1.84 billion. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.Agilent Technologies’s quarterly revenue was up 8.1% on a year-over-year basis. During the same period last year, the business posted $1.37 EPS. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, equities research analysts expect that Agilent Technologies will post 6.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Core Wealth Advisors LLC acquired a new position in Agilent Technologies in the fourth quarter valued at $26,000. SHP Wealth Management purchased a new stake in Agilent Technologies in the 4th quarter valued at about $26,000. Navalign LLC purchased a new stake in Agilent Technologies in the fourth quarter valued at approximately $27,000. Cedar Mountain Advisors LLC purchased a new stake in Agilent Technologies in the first quarter valued at approximately $27,000. Finally, Markowski Investments acquired a new position in Agilent Technologies during the second quarter worth approximately $27,000. Hedge funds and other institutional investors own 87.41% of the company’s stock.

Key Headlines Impacting Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported fiscal Q3 revenue of $1.88 billion, up 8.1% year over year and above the $1.84 billion consensus estimate. Adjusted EPS of $1.62 also exceeded expectations of $1.49, while earnings rose from $1.37 a year earlier. Operating profit and cash flow improved, supporting the view that demand for laboratory, pharmaceutical research, and analytical instruments is recovering. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 outlook to adjusted EPS of $6.18-$6.21, above the $6.06 analyst consensus, and forecast revenue of approximately $7.5 billion versus expectations of $7.4 billion. Fourth-quarter EPS guidance of $1.71-$1.74 was at or above consensus, reinforcing confidence in improving demand and expanding margins. Agilent raises annual profit forecast on improving lab tools demand
• Positive Sentiment: Several analysts raised their price targets and adopted bullish ratings following the results. JPMorgan lifted its target to $190 and rated the stock “overweight”; RBC raised its target to $185 with an “outperform” rating; and TD Cowen and Bernstein increased targets to $180, with “buy” and “outperform” ratings, respectively. The revisions signal that analysts see additional upside after the earnings beat and guidance increase. Analyst price-target revisions reported by Benzinga

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.